Search Results - technology+classifications+%3e+therapeutic+modalities+%3e+biologics

99 Results

Sort By:

Targeted T-VEC immunotherapy for cutaneous neurofibromas

Value Proposition· Tumor-selective oncolysis: T‑VEC is an engineered oncolytic HSV‑1 that preferentially replicates in and lyses tumor cells, providing direct cytolytic reduction of cutaneous neurofibromas in preclinical models· Local, anti-tumor immune activation: preclinical evidence that tumor cell lysis and local GM-CSF expression promotes...

Published: 4/24/2026 | Inventor(s): Renyuan Bai, Verena Staedtke, Jaishri Blakeley, Carlos Romo

Keywords(s):

Category(s): Clinical and Disease Specializations > Genetic Diseases, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Repurposed Drugs, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Immunotherapies, Clinical and Disease Specializations > Immuno-Oncology

Novel HPV Vaccine

C10218: L2 Lipopeptide Vaccine for Prevention of Human Papillomavirus Infection Value Proposition: • A broadly protective vaccine against HPV. • Can be delivered without needles. • Can be chemically synthesized at low cost. Technical Details: Human papillomavirus (HPV) infections are the most common sexually transmitted infection in the...

Published: 4/23/2026 | Inventor(s): Hannah Alphs-Jackson, Ratish Gambhira, Richard Roden

Keywords(s): Biologics, Cancers, Disease Indication, Therapeutic Matter, Therapeutic Substance, Therapeutics, Vaccine

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Vaccines, Technology Classifications > Therapeutic Modalities

Out for review, Need to check with Tulane whether we can post it or not.

Unmet Need There are significant roadblocks to the routine delivery of macromolecules such as proteins, peptides, imaging agents, polysaccharides and more to the cytosol of mammalian cells. While most macromolecules are easily directed to existing cellular uptake mechanisms, they are often trapped in endosomal pathways leading to lysosomal degradation...

Published: 4/24/2026 | Inventor(s): Kalina Hristova, Gregory Wiedman, William Wimley, Sarah Kim

Keywords(s): Biologics, Drug Delivery Vehicle, Peptide, Peptides/Prodrugs, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Peptides, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities

Targeting of Myeloid-Derived Suppressor Cells (MDSCs) for Cancer Treatment

Value Proposition· Addresses key resistance mechanism: targets MDSCs, a central driver of resistance to immune checkpoint inhibitors in metastatic and poorly immunogenic cancers· Synergistic combination strategy: Combines epigenetic modulators (HDAC and DNA methyltransferase inhibitors) with anti-PD-1 and anti-CTLA-4 antibodies to restore...

Published: 4/23/2026 | Inventor(s): KiBem Kim, Bert Vogelstein, Kenneth Kinzler, Shibin Zhou

Keywords(s): Antagonists/Inhibitors, Antibodies, Biologics, Cancers, Combination, Disease Indication, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Targeted Therapy/Immunotherapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities

GAS6-Modified Extracellular Vesicles (EVs) for Anti-Inflammatory Therapy

Value Proposition· Superior Anti-Inflammatory Potency: This membrane-associated GAS6 demonstrates over 10-fold higher anti-inflammatory activity compared to equivalent amounts of soluble recombinant GAS6 proteins. · Dual Mechanism of Action: Inhibits pro-inflammatory cytokine production and concurrently stimulates anti-inflammatory responses,...

Published: 4/24/2026 | Inventor(s): Kenneth Witwer, Matias Ostrowski, Martina Fabiano, Alan Adamczyk

Keywords(s):

Novel Anti-Angiogenic Collagen Derived Mimetic Peptides

C11348: Novel Anti-Angiogenic Collagen Derived Mimetic PeptidesNovelty:modified peptides from collagen IV derived parent peptide Pentastatin-1Value Proposition:The invention describes the synthesis of novel anti-angiogenic by substituting particular amino acids of the peptide Pentastatin-1 derived from collagen IV. Other advantages include:• Ability...

Published: 4/23/2026 | Inventor(s): Niranjan Pandey, Elena Rosca, Corban Rivera, Jacob Koskimaki, Amir Tamiz, Aleksander Popel

Keywords(s): Biologics, Cancers, Disease Indication, Peptide, Protein, Single, Targeted Therapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Proteins, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities

Polymeric particles for sustained delivery of multimodal peptide therapeutics

Value Proposition· Stability: polymeric nanoparticle encapsulation increases and sustains peptide residence time, for increased accumulation in tissue vasculature and maximize treatment effects· Safety: use of nanoparticles reduces toxicity by confining peptide delivery to site of administration· Flexible formulation approaches: system's...

Published: 4/23/2026 | Inventor(s): Jordan Green, Aleksander Popel, Joel Sunshine, Ron Shmueli, Stephany Tzeng, Kristen Kozielski

Keywords(s): Biologics, Drug Delivery Vehicle, Nucleic Acid, Peptide, Polymers, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Dendrimers & Polymers, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Peptides, Technology Classifications > Therapeutic Modalities

Novel monoclonal antibody inhibitors targeting potassium channel KCNK9

Unmet Need:KCNK9 is one of 15 mammalian subtypes in the highly conserved family of two-pore domain potassium channels (K2P). Under physiological conditions, KCNK9 is primarily expressed in the brain where it serves to maintain cellular membrane potentials. However, overexpression of KCNK9 has been detected in breast, lung, skin, and other cancers, and...

Published: 4/23/2026 | Inventor(s): John Laterra, Han Sun, Min Li, Amy Fulton

Keywords(s): Antibodies, Biologics, Breast Cancer, Cancers, Disease Indication, Lung Cancer, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Respiratory Diseases, Clinical and Disease Specializations > Women's Health, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Breast Cancer, Clinical and Disease Specializations > Oncology > Lung Cancer

Novel Immunotherapy for Pulmonary Remodeling Diseases

Unmet NeedAutoinflammatory responses, your body’s innate defense mechanism against infections and stressors, can become overactive and cause chronic inflammation in various tissues and organs. Inflammatory diseases affect more than 200 million people worldwide and include pulmonary hypertension, scleroderma, rheumatoid arthritis, pulmonary fibrosis,...

Published: 4/23/2026 | Inventor(s): Roger Johns

Keywords(s): Antibodies, Biologics, Cardiovascular Diseases, Disease Indication, Hypertension, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics, Clinical and Disease Specializations > Cardiovascular, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Cardiovascular > Hypertension

CRISPR/Cas9 and Tumor-Specific Guide RNAs as a Specific and Selective Cancer Cell Killing Biologic Platform

Value Proposition:Specific targeting of mutations can treat any cancer with the specified mutations.Selective cell killing spares healthy tissue while eliminating cancer cells. Pan-cancer efficacy as guide RNAs are developed to target a wide breadth of cancer-specific mutations.Lack of protospacer adjacent motif (PAM) sites in healthy host cells prevents...

Published: 4/24/2026 | Inventor(s): James Eshleman, Selina Shiqing Teh, Kirsten Bowland, Nicholas Roberts

Keywords(s):

Category(s): Clinical and Disease Specializations > Oncology, Clinical and Disease Specializations > Oncology > Pancreatic Ductal Adenocarcinoma, Clinical and Disease Specializations > Oncology > Pancreatic Cancer, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Research Tools > Nucleic Acids

1 2 3 4 5 6 7 8 9 10